Kenvue Likely to Report Weaker Q2 Amid Ongoing Challenges, RBC Says
Looking At Johnson & Johnson's Recent Unusual Options Activity
Express News | J&J - Depuy Synthes Launches Its First Active Spine Robotics and Navigation Platform
DePuy Synthes Launches Its First Active Spine Robotics and Navigation Platform
The Bank of Japan's hawkish stance and escalating economic recession concerns resulted in the Japanese stock market falling for the second consecutive day.
Due to market expectations that Japan's central bank will further tighten monetary policy, the Japanese stock market has plummeted for the second consecutive day.
Value Stocks Trounced Growth in July. Rate Cuts Could Keep The Rally Going.
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Express News | FDA Says Do Not Use Megadyne Mega Soft Pediatric Patient Return Electrodes In Any Age Group; Only Use Megadyne Mega 2000, Mega Soft Patient Return Electrodes On Patients 12 Years & Older
Express News | FDA: Only Use Megadyne Mega 2000, Mega Soft Patient Return Electrodes (Product Codes: 0800,0830,0835,0845,0846,0847,0848) On Patients 12 Years& Older
Express News | FDA: Do Not Use Megadyne Mega Soft Pediatric Patient Return Electrodes (Product Code 0840) in Any Age Group
Express News | Chmp Recommends Rybrevant®▼ (Amivantamab) in Combination With Chemotherapy for the Treatment of Adult Patients With Advanced Egfr-Mutated Non-Small Cell Lung Cancer (Nsclc) After Failure of Prior Therapy
J&J Wins Another FDA Label Expansion for Multiple Myeloma Therapy
Express News | Reported Earlier, Johnson & Johnson's DARZALEX FASPRO Quadruplet Therapy Approved By FDA For Initial Treatment Of Multiple Myeloma
Another round of pre-announcement before the release! Will Japan raise interest rates and shrink its balance sheet at the same time? Technology stocks plummeted in response to the news overnight, and the Japanese yen rose.
NHK reports that the Bank of Japan is discussing raising interest rates to 0.25%, and combined with previous analyses, the central bank may propose specific measures to reduce the balance sheet at this meeting. Will this 'double whammy' affect global markets today?
Express News | J&J - Findings From Quadruplet Therapy Study With Subcutaneous Darzalex Faspro Showed 60% Reduction in Risk of Disease Progression or Death
Express News | Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients With Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Express News | FDA Approves Daratumumab and Hyaluronidase-Fihj With Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Cantor Fitzgerald Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $215
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
Express News | Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target